4.7 Editorial Material

FDA Approval of Tisagenlecleucel Promise and Complexities of a $475 000 Cancer Drug

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 318, Issue 19, Pages 1861-1862

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2017.15218

Keywords

-

Funding

  1. Association of Community Cancer Centers
  2. America's Health Insurance Plans
  3. AIM Specialty Health
  4. American College of Chest Physicians
  5. American Society of Clinical Oncology
  6. Barclays
  7. Express Scripts
  8. Genentech
  9. Goldman Sachs
  10. McKinsey and Company
  11. MPM Capital
  12. National Comprehensive Cancer Network
  13. Biotechnology Industry Organization
  14. American Journal of Managed Care
  15. Boston Consulting Group
  16. Foundation Medicine
  17. Anthem
  18. Novartis
  19. Excellus Health Plan
  20. Kaiser Foundation Health Plan
  21. National Institutes of Health
  22. Laura and John Arnold Foundation
  23. Defined Health

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available